PKD2 and autosomal dominant polycystic kidney disease: RGLS4326 is specifically developed to inhibit the pathological functions of the miR-17 family in autosomal dominant polycystic kidney disease (ADPKD) [189], one of the most frequent monogenic disorders, caused by mutations in the PKD1 or PKD2 gene and for which therapeutic options are limited.